The impact of the patient voice in HTA submissions

Reimagining the Global Value Dossier - Part 4

BY Silvy Mardiguian, Principal Consultant, and Ebony Samuels, Vice President, Access Consulting, Parexel - 11.25.19

Health Technology Assessment (HTA) agencies are increasingly demanding the inclusion of patient-relevant data in submission dossiers. It is evident that there is an effort to ensure patients’ interests are considered in HTA evaluations. Most stakeholders agree that patients should be more involved in HTA evaluations as they can help decision-makers understand the disease burden and the impact of the intervention on their quality of life. However, how much weight does the patient voice have in HTA assessments?

There is currently very little transparency or feedback on how patient input translates into decisions. Reviews of oncology drugs and drugs for rare diseases are more likely to include patient and advocacy group submissions than non-rare and non-oncology reviews, suggesting that disease severity and end-of-life considerations may be major factors in these submissions. However, there is little evidence to suggest that patient and advocacy groups impact on HTA decisions substantially.

Despite this, the number of patient and advocacy group submissions has been increasing over time suggesting a trend towards greater patient involvement and a greater willingness from HTA bodies to hear the patient voice. Indeed, many of the prominent HTA agencies around the world have formal mechanisms to engage with patient groups during HTA evaluations. Patients, particularly when well organised, can be a powerful force that produces change by asserting their influence on HTA agencies and governments. Therefore, pharmaceutical companies need to ensure that patient-relevant data is included and communicated clearly so that patients are well equipped to inform HTA submissions, leading to more patient-centric HTA decisions.

At Parexel, we understand the importance of communicating the value of a product to all stakeholders, including patients, in a way that is relevant, insightful, and engaging.

Look out for our launch of a new approach to the GVD over the coming weeks, or contact ebony.samuels@parexel.com to discuss how we could transform your GVD today.


We are always available for a conversation.

*